PRODUCTS
Multi Plex Matrix MPM-R14H00
Indication: INTESTINAL INFLAMMATION
MPM-R14H00 possesses an anti-inflammatory effect in gastrointestinal diseases comparable to 5-ASA in ulcerative colitis model.
MPM-R14H00 was tested in dextran sulfate salt model while monitoring the overall health of the animal (weight loss, colon length, clinical scores).
MPM-R14H00 limits the weight loss associated with gastrointestinal diseases (dehydration).
MPM-R14H00 reduces the symptoms of gastro-intestinal inflammation such as diarrhoea and blood feces.
MPM-R14H00 slows down the destructive process of gastrointestinal inflammation and helps the remission of the animals following the acute inflammation.
Recognition of MPM-R14H00 bacterial CpG motifs and PAMPs by TLR9 is likely to lead to an increased activity of regulatory T cells, controlling inflammation by expressing anti-inflammatory cytokines such as IL-10 and TGFb, through production of IFNa by dendritic cells.
Technical Targeted Health Claim
Management of gastrointestinal diseases: Ulcerative Colitis, Crohn’s Disease and IBS
Weight variation during the intestinal inflammatory animal model.
Colon length representing the inflammatory level during the intestinal inflammatory acute phase.